Once a darling of the health care space (and a frequent member of "buy and hold forever" lists), Teva Pharmaceuticals (NYSE: TEVA )
spent about three and a half years in the market's doghouse. Investors
bailed out due to worries about competition in the company's lucrative
MS franchise, the perception of a dwindling pipeline for major generics,
and turmoil in executive leadership. Now it looks as though the company
has shored up its MS franchise, rejuvenated its R&D efforts, and
become more serious about driving better value in/from the business.
Please click here to read more:
Is Teva Pharmaceutical Industries Ltd Turning a Corner?
No comments:
Post a Comment